A novel inhaled therapy targeting a key driver of airway inflammation has shown encouraging early results in patients with moderate‑to‑severe asthma, offering hope for a more convenient and targeted treatment option.
In their paper, “AZD8630/AMG 104, An Inhaled Anti-TSLP Antibody Fragment for Moderate-to-Severe Asthma: A Phase 1 Randomized Controlled Trial,” researchers reported findings from the first human trial of AZD8630 (also known as AMG 104). The experimental inhaled biologic is designed to block thymic stromal lymphopoietin (TSLP) — a protein that plays a central role in initiating and sustaining airway inflammation in asthma. The study was published in the Journal of Allergy and Clinical Immunology.
AZD8630 differs from many existing biologic therapies that are administered through injections or infusions. Rather, the drug is delivered via inhalation, allowing it to act directly in the lungs. This localized approach, authors noted, could mark a major shift in asthma care, potentially improving both treatment effectiveness and patient convenience.
The drug works by targeting TSLP, an upstream inflammatory signaling molecule often described as an “alarm cytokine” in asthma. By blocking TSLP, scientists aim to interrupt the cascade of inflammation before it fully develops.
The study, a phase 1 randomized, controlled trial, included 181 participants across two groups:
- Healthy adults
- Adults with moderate‑to‑severe asthma
Participants received varying doses of AZD8630 or a placebo over periods ranging from 14 to 28 days.
The results were notable:
- Patients who received the highest dose experienced a 23% reduction in FeNO (fractional exhaled nitric oxide) — a key biomarker of airway inflammation.
- Researchers observed dose‑dependent pharmacokinetics, meaning the drug’s behavior in the body scaled predictably with dosage.
- The therapy showed an acceptable safety profile, with minimal immune reactions to the drug.
Beyond safety, the study demonstrated what researchers call “proof‑of‑mechanism” — evidence that the drug is successfully engaging its intended biological target.
Patients demonstrated:
- Decreased levels of free TSLP
- Increased levels of the drug‑bound TSLP complex
Researchers said these findings confirm that AZD8630 is actively blocking the inflammatory pathway it was designed to target.
The study further reinforced the notion that the emergence of an inhaled biologic therapy could represent a major advance by:
- Delivering treatment directly to the lungs
- Potentially reducing systemic side effects
- Simplifying administration through once‑daily dosing
AZD8630’s pharmacological profile supports standard inhaler‑based daily use, which could improve adherence among patients, authors noted.
Although the results are promising, the study’s authors cautioned that this is an early‑stage trial, primarily designed to assess safety rather than long‑term clinical outcomes.
They encouraged future research to include:
- Larger trials to determine optimal dosing
- Studies evaluating whether the drug improves symptoms, lung function and exacerbation rates
- Longer-term safety assessments
Researchers concluded that the findings support continued development of AZD8630, particularly for patients with moderate‑to‑severe asthma who may not respond adequately to existing therapies.
If future studies confirm these early findings, the study’s authors noted that AZD8630 could become part of a new generation of targeted, inhaled biologics — combining the precision of advanced immunotherapy with the practicality of inhalation delivery.
